We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Provention Bio Inc | NASDAQ:PRVB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.98 | 25.04 | 24.90 | 0 | 01:00:00 |
From Jul 2022 to Jul 2024
By Josh Beckerman
Provention Bio Inc. shares rose 8% to $8.91 after hours as the U.S. Food and Drug Administration approved Tzield, which the agency called the "first drug that can delay onset of Type 1 diabetes."
The injection was approved as a treatment to delay the onset of stage 3 type 1 diabetes in adults and children 8 and older who currently have stage 2 type 1 diabetes.
Provention said the Tzield approval "is a historic occasion for the T1D community and a paradigm-shifting breakthrough."
Meanwhile, MacroGenics Inc. said it has earned a $60 million milestone payment due to the approval. MacroGenics shares were up 5% at $6.89 after hours.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 17, 2022 18:42 ET (23:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Provention Bio Chart |
1 Month Provention Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
